Steven C. Gilman, a director at Vericel Corp (NASDAQ:VCEL), recently sold a substantial amount of the company's stock. According to a filing with the Securities and Exchange Commission, Gilman sold 5,833 shares of Vericel common stock on October 16 at a price of $41.36 per share, totaling approximately $241,252. This transaction was part of an automatic sale under a Rule 10b5-1 trading plan that Gilman adopted earlier this year.
On the same day, Gilman also exercised stock options to acquire 5,833 shares at a price of $13.05 per share. Following these transactions, Gilman holds 11,000 shares of Vericel.
In other recent news, Vericel Corporation has been making significant strides with its product portfolio. The U.S. Food and Drug Administration (FDA) has approved Vericel's MACI Arthro, a product for arthroscopic knee repair, and NexoBrid for pediatric use. The FDA approval of MACI Arthro, which is less invasive than traditional methods, is expected to expand Vericel's surgeon base from 5,000 to 7,000 and could potentially benefit around 20,000 patients annually.
The FDA's nod for NexoBrid marks an expansion of its usage to approximately 20 pediatric burn centers across the United States. These developments are seen as a significant expansion of Vericel's current offerings.
Analysts from BTIG and TD Cowen have maintained a Buy rating on Vericel's stock, reflecting confidence in the company's direction. Canaccord Genuity has initiated coverage on Vericel, also assigning a Buy rating.
Vericel reported a record revenue of nearly $53 million for the second quarter of 2024, driven by growth in their MACI product and solid demand for NexoBrid. The company also raised its profitability outlook for the year. These are recent developments that underline the ongoing momentum at Vericel Corporation.
InvestingPro Insights
While Steven C. Gilman's recent stock sale might raise eyebrows, it's crucial to consider Vericel Corp's (NASDAQ:VCEL) broader financial picture. According to InvestingPro data, Vericel boasts a market capitalization of $2.04 billion, reflecting significant investor confidence in the company's potential. The company's revenue growth of 20.39% over the last twelve months as of Q2 2024 indicates strong business momentum.
InvestingPro Tips highlight that Vericel is expected to see net income growth this year, which could explain the high earnings multiple at which the stock is currently trading. The company's P/E ratio stands at a lofty 2,590, suggesting investors are pricing in substantial future growth. Additionally, Vericel operates with a moderate level of debt, which provides financial flexibility for future expansion.
It's worth noting that Vericel's stock price movements are quite volatile, as pointed out by another InvestingPro Tip. This volatility, combined with the company's high valuation multiples, underscores the importance of careful consideration for potential investors. For those seeking a more comprehensive analysis, InvestingPro offers 11 additional tips that could provide valuable insights into Vericel's investment potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.